N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
N/A N=445 Factors Affecting Mortality in Critical Patients Admitted to Intensive Care Unit Due to Coronavirus Disease 2019
Covid19 and Mortality
Primary: Acute Physiology and Chronic Health Evaluation II Score — 13.1; 18.3 score on a scale
Phase 2 N=29 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
Corona Virus Infection · SARS-CoV 2 · SARS Pneumonia
Primary: Number of Participants Transferred to Intensive Care Unit (ICU) — 4 Participants
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
Phase 2 N=56 Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
COVID-19
Primary: Total Number of Serious Adverse Events (SAE) Through Study Day 14 — 0; 0 Serious Adverse Events
Phase 2 N=212 A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Critical Confirmed Coronavirus Disease (COVID)-19
Primary: Time to Sustained Improvement of at Least 2 Categories on 6-point Ordinal Clinical Recovery Scale (CRS): Primary Analysis Set — 17.00; 23.00 Days
Phase 2 N=180 Convalescent Plasma to Stem Coronavirus (CSSC-001)
Coronavirus · Convalescence
Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=877 Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
COVID-19
Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants
Phase 2 N=34 Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
COVID-19 · Sars-CoV2
Primary: Mechanical Ventilation or Death Endpoint — 2; 0 Participants
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
N/A N=93 Rapid, Onsite COVID-19 Detection
COVID-19 · Sars-CoV2
Primary: Number of Samples Tested — 3692 samples
N/A N=55 Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma
Covid19
Primary: Adaptive COVID-19 Treatment Trial Scale (ACTT) Version II — 0; 0; 0; 0 Participants
Phase 2 N=124 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19)
Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants
Early Phase 1 N=10 COVID-19 Convalescent Plasma
Coronavirus
Primary: Success of Administering Plasma — 10; 0 Participants
N/A N=330 Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
COVID-19
Primary: Number of Subjects With Sustained Resolution of COVID-19 Signs and Symptoms Without Subsequent Symptom Recurrence or Disease Progression (Until the End of the Study)…
N/A N=224 Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Prone Positioning · High Flow Nasal Cannula · Acute Respiratory Distress Syndrome
Primary: Treatment Failure (Intubation or Death) — 45; 45 Participants
Phase 2 N=83 Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
COVID-19 Pneumonia · Acute Lung Injury · ARDS
Primary: Number of Subjects Alive and Free of Respiratory Failure — 26; 20 Participants — p=0.0440
Phase 1 N=53 RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19
Covid19
Primary: Total Protein Normal to Abnormal Transition — 4.5; 4.6 percentage of participants — p=1.000
N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
Phase 3 N=814 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
COVID
Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598
Phase 2 N=32 Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis
COVID-19
Primary: Number of Participants With Clinical Response in Maximum Temperature (Tmax) — 8; 16 Participants
N/A N=2,097 COVID-19 Watch + COVID-19 Pulse
Covid19
Primary: Difference in Days Alive and Out of Hospital — 29.5; 29.4 days
N/A N=153 Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)
Infectious Disease · Cancer · Coronavirus Infection
Primary: Percentage of Patients at Each Sample Timepoint With a Positive Detection of Immunoglobulin G (IgG) Specific Antibodies to SARS-CoV-2 (Spike-protein). — 34.9; 38.3…
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants